SHENZHEN, China, July 12, 2024 /PRNewswire/ -- On July 5th, the 2nd Ambulatory Glucose Profile
(AGP) & Digital Therapeutics (DTx), led by the National
Innovation Center for Advanced Medical Devices, sponsored by China
AGP and DTx Digital Therapeutics R&D Center ("R&D Center"),
co-sponsored by Shenzhen SIBIONICS Technology Co.,
Ltd. ("SIBIONICS"), took place in Shenzhen, China. Domestic and overseas
healthcare experts converged at the Summit Forum to explore the
application of AGP in precision diagnosis and treatment of
diabetes, and digital therapeutics during the decision-making
process of clinical practice worldwide.
The Summit Forum, hosted by Professor Ji
Linong, initiator of the China AGP&DTx R&D Center
and clinical professor at Peking University People's Hospital,
featured top endocrinology experts from Slovenia, Australia, Saudi Arabia Serbia, Turkey, Algeria, and beyond. Experts explored critical
topics including AGP consensus, the Chinese diabetes patient
database, artificial pancreas system, and digital health
management. They also discussed the latest advancements in diabetes
management technology and their practical applications in clinical
practice.
At the conference, Professor Andrej
Janež, Head of the Department of Endocrinology at the
Ljubljana University Medical Centre in Slovenia, highlighted China's advancements in AGP clinical practice.
He remarked, "They've developed an AGP training program, and
they're moving into the area of researching and using AI to enhance
diagnosis and guide treatment decisions, leading to better diabetes
care and facilitating AGP applications."
To integrate global resources and drive innovation in diabetes
diagnosis and treatment, the International Consortium for
AGP&DTx R&D was founded at this forum. This initiative aims
to standardize AGP clinical applications globally and provide
a platform for international collaboration and knowledge
sharing to elevate diabetes diagnosis and
treatment worldwide.
About SIBIONICS
Founded in 2015, SIBIONICS is committed to the R&D and
industrialization of implantable medical devices. By merging
cutting-edge CGM technology with designs centered around diabetes
patients, SIBIONICS strives to push the boundaries of what's
possible in personalized diabetes management solutions. With over
1,000,000 users globally, SIBIONICS is now a beacon of reliability
and innovation in diabetes management.
Photo -
https://mma.prnewswire.com/media/2459986/Shenzhen_Hosts_the_2nd_AGP_DTx_Summit_Forum_Press_Image.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/shenzhen-hosts-the-2nd-agpdtx-summit-forum-advancing-digital-therapeutics-in-diabetes-management-302195718.html